Comparative Study Between Glimepiride and Glibenclamide in the Treatment of Type 2 Diabetic Patients in Al-Yarmouk Hospita


ABSTRACT: BACKGROUND: Second-generation sulfonylureas (SU) are efficacious, generally well-tolerated, cost-effective options for the medical management of diabetes. Glimepiride which is sometimes classified as athird-generation has benefits over other in that it has a considerably lower binding affinity for theB-cell receptor, result in a modulation of insulin release, and a decreased potential for inducinghypoglycemia. OBJECTIVE: This study was designed to evaluate the outcome of using glimepiride and glibenclamide in type 2diabetic patients.PATIENTS AND METHODS: A single blinded randomized clinical trial was adopted, in which 64 already diagnosed diabeticpatients (regardless disease duration) were recruited from Al-Yarmouk hospital, and randomizedinto two groups; 1INTRODUCTION:Sulfonylureas have been used for type 2 diabetesfor over 50 years (1). They act by stimulatinginsulin release from the beta cells of thepancreas. They bind to sulfonylurea receptorsfound on the surface of pancreatic β-cells andthis interaction leads to closure of K-ATPchannels, the cell membrane is depolarized andinsulin is released (2)st group (32 patients) treated with 5 mg glibenclamide, and 2 group (32patients) treated with 3 mg glimepride for 4 months. Fasting blood sugar (FBS), glycosylatedhemoglobin (HbA1c) level, triglyceride, cholesterol, serum electrolyte (Na, K, Ca) level and pulserate were measured at zero time (first visit)and at the end of the study (after 4 months).RESULTS: The result showed that both Fasting blood sugar, glycosylated hemoglobin, serum total cholesterol,triglyceride levels were decreased significantly in both treatment group but with greater reductionin group 2, serum electrolytes were not significantly affected, except calcium level which wasincreased significantly in glimepiride group only. Moreover, no significant effect observedregarding pulse rate compared to pretreatment period.CONCLUSION: Glimepride provide more potent glycemic control and better lipid profile compared toglibenclamide in type 2 diabetic patients